mProX™ Human BCR Stable Cell Line

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Leukemia, Chronic Myeloid; B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)

Gene ID

Human:613

UniProt ID

Human:P11274

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The Breakpoint Cluster Region (BCR) gene plays a pivotal role in cellular signaling and is most notably recognized for its association with the Philadelphia chromosome, a translocation between chromosomes 9 and 22. This translocation results in the BCR-ABL fusion gene, which is implicated in several types of leukemia, including chronic myeloid leukemia (CML). The BCR-ABL protein has constitutive tyrosine kinase activity, leading to uncontrolled cell proliferation. Research into BCR has paved the way for targeted therapies, such as tyrosine kinase inhibitors, which have revolutionized the treatment of CML and improved patient outcomes significantly.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human BCR Stable Cell Line (S01YF-1023-PY147). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Alex Davis (Verified Customer)

What is the significance of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia? Nov 24 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

BCR-ABL tyrosine kinase inhibitors, like STI571, have shown significant antileukemic activity and are well-tolerated in chronic myeloid leukemia. Nov 24 2021

chat Peyton Davis (Verified Customer)

How does BCR-ABL gene mutation or amplification affect cancer therapy resistance? Jul 19 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Drug resistance in cancer therapy is often associated with the reactivation of BCR-ABL signal transduction. Jul 19 2020

Published Data

Fig.1 In the context of diminished Bcr levels, a noticeable upregulation in the expression of the c-Myc protein was observed.

The influence of Bcr on c-Myc expression was investigated using short interfering RNA (siRNA) oligonucleotides. In this study, HEK293 cells were subjected to transfection with Bcr-specific siRNA duplexes at concentrations of 50 or 100 nM, alongside an unrelated interleukin-12 (IL-12) siRNA as a control, which successfully suppressed IL-12 expression while leaving Bcr messenger RNA unaffected. Immunoblots (IB) with DL are presented as specified, illustrating the experimental outcomes.

Ref: Ress, Angelika, and Karin Moelling. "Bcr is a negative regulator of the Wnt signalling pathway." EMBO reports 6.11 (2005): 1095-1100.

Pubmed: 16211085

DOI: 10.1038/sj.embor.7400536

Research Highlights

Chen, Dong; K, Olga. "Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms." International journal of laboratory hematology, 2023.
The final stage of BCR::ABL1-negative myeloproliferative neoplasm (MPN-BP), known as the blast phase, is characterized by complex genomic changes. These changes involve alterations in the sequences of DNA and RNA, which can result in either the loss or gain of function of important proteins. These proteins include adaptor proteins, enzymes, spliceosome components, cell cycle regulators, transcription factors, and cell signaling proteins. Modifications at different levels, such as transcription, translation, and post-translational modification, can further contribute to these alterations. Mutated genes such as ASXL1, EZH2, IDH1, IDH2, TET2, SRSF2, U2AF1, TP53, NRAS, KRAS, PTPN11, SH2B3/LNK, and RUNX1 are involved in the progression of MPN-BP by influencing the expression, modification, and function of genetic material. This review provides a comprehensive summary of these mutations and their role in the progression of MPN-BP.
Chen, Dong; K, Olga. "Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms." International journal of laboratory hematology, 2023.
Pubmed: 37867386 DOI: 10.1111/ijlh.14184

Zhang, Xiuyan. et al. "A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells." Cellular & molecular biology letters, 2023.
The role of Zinc finger protein X-linked (ZFX) in promoting tumor cell growth, particularly in leukemic cells, has been extensively studied. However, its impact on the growth and drug response of chronic myeloid leukemia (CML) stem/progenitor cells has yet to be fully elucidated. Further research is needed to understand the involvement of ZFX in CML and its potential as a target for therapeutic intervention.
Zhang, Xiuyan. et al. "A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells." Cellular & molecular biology letters, 2023.
Pubmed: 37864206 DOI: 10.1186/s11658-023-00496-z